🇺🇸 FDA
Pipeline program

MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE

MK-5684-015

Phase 3 small_molecule active

Quick answer

MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE for Breast cancer, Ovarian cancer, Endometrial cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Breast cancer, Ovarian cancer, Endometrial cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials